Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Women with premature ovarian insufficiency on HT likely to have poor sleep quality

10 Aug 2019

Women who have premature ovarian insufficiency (POI) and are receiving hormone therapy (HT) appear to have poor sleep quality, taking longer to fall asleep and experiencing greater fatigue, according to a recent study.

The cross-sectional study involved 61 women with POI receiving HT (POI group; mean age, 35.03 years) and an identical number of age-matched women with preserved ovarian function (control group; mean age, 34.49 years).

Researchers evaluated sleep quality and fatigue using the Pittsburgh Sleep Quality Index (PSQI) and Chalder Fatigue Scale, respectively. They performed correlation analysis, the Mann-Whitney, chi-square, or Fisher test to compare the said outcomes between the POI and control groups.

Results for the PSQI evaluation showed no significant between-group difference, with mean scores of 7.69 in the POI group and 8.03 in the control group (p=0.79).

However, women in the POI group had higher and therefore worse scores for the sleep latency component (mean, 1.74 and 1.18, respectively; p<0.001) and were more likely to use sleep medications (mean, 1.28 and 0.85; p=0.008). Furthermore, fatigue index was markedly higher than in the control group (mean, 5.25 and 3.49, respectively; p<0.001).

In the POI group, sleep quality was graded as poor in 69 percent of women, while fatigue was present in 59 percent.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.